Propel Bio Partners

Achieve Life Sciences Inc., headquartered in Vancouver, Canada, is a clinical-stage pharmaceutical company focused on developing and commercializing cytisine, a plant-based alkaloid, as a smoking cessation aid. Cytisine interacts with nicotine receptors in the brain to help reduce withdrawal symptoms associated with quitting smoking. The company has license agreements with Sopharma AD and University of Bristol for this purpose. Achieve Life Sciences aims to address the global smoking health epidemic by advancing cytisine as a widely available treatment option.

Inherent Biosciences is a molecular diagnostics company focused on transforming the traditional trial and error approach in medicine. The company leverages its innovative epigenetic medicine platform to address various health challenges by identifying gene dysregulation and its associated pathways. By translating biological insights into actionable information, Inherent Biosciences aims to enhance treatment strategies for conditions such as pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. This approach not only guides healthcare professionals in managing complex diseases but also seeks to provide personalized insights that empower patients in their health journeys.

Persephone Biome, Inc. is a San Diego-based company focused on researching and developing products and therapies that modify gut microbial metabolism, particularly in relation to cancer treatment. Established in 2017, the company is creating innovative solutions aimed at enhancing the efficacy of oncology drugs by retuning the gut microbiome. This includes the development of a pill containing beneficial gut bacteria. In addition to its therapeutics, Persephone Biome aims to offer nutritional products that support the human gut microbiome, producing functional foods and beverages that cater to the growing consumer demand for health-oriented products. The company has plans to enter clinical trials to further advance its initiatives in the field of microbiome-directed therapies.

OmniVis is a biotechnology company specializing in pathogen detection. It offers an integrated portable platform that rapidly and accurately identifies pathogens in various environments, reducing the need for labor-intensive lab testing.